atp5if1b Antibody

What is ATP5IF1 and why is it significant in cellular biology?

ATP5IF1 (ATP synthase inhibitory factor subunit 1) is a critical regulatory protein of the mitochondrial ATP synthase complex. This canonical protein in humans consists of 106 amino acid residues with a molecular mass of 12.2 kDa and is primarily localized within mitochondria. ATP5IF1 belongs to the ATPase inhibitor protein family and plays a crucial role in modulating ATP synthesis by reversibly inhibiting the F₁F₀ ATP synthase during periods of oxygen limitation or mitochondrial dysfunction . Its significance extends beyond basic energy metabolism, as it has been implicated in angiogenesis and erythrocyte differentiation processes, making it a valuable target for various research applications .

How many isoforms of ATP5IF1 exist and how do they differ functionally?

Current research indicates that up to three different isoforms of ATP5IF1 have been reported in human tissues . These isoforms result from alternative splicing events and post-translational modifications. While the canonical isoform is well-characterized as a mitochondrial protein regulating ATP synthesis, the functional specialization of other isoforms remains an active area of investigation. Research suggests that these variant forms may exhibit tissue-specific expression patterns and potentially distinct regulatory roles depending on cellular contexts and metabolic states . Understanding these isoform differences is essential for designing targeted experimental approaches and selecting appropriate antibodies for specific research questions.

What species orthologs of ATP5IF1 have been identified for cross-reactivity studies?

ATP5IF1 is highly conserved across various species, making cross-reactivity studies feasible and informative. Research has confirmed the presence of ATP5IF1 gene orthologs in multiple experimental model organisms including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken . This conservation reflects the fundamental importance of ATP synthase regulation across evolutionary lineages. When conducting cross-species studies, researchers should note that despite sequence homology, species-specific variations in epitope structures may affect antibody recognition and binding efficiency. Validation experiments are therefore recommended when applying ATP5IF1 antibodies across different species models.

What are the most validated applications for ATP5IF1 antibodies in current research?

Based on comprehensive literature review and product validation data, ATP5IF1 antibodies have been successfully employed across multiple experimental methodologies. Western Blot represents the most widely used and thoroughly validated application, providing reliable detection of ATP5IF1 protein expression levels . Other well-established applications include Immunocytochemistry (ICC), Immunofluorescence (IF), and Immunohistochemistry (IHC), which enable spatial localization studies of ATP5IF1 within cellular and tissue contexts . Flow cytometry applications, while less common, have also been reported in the literature for quantitative single-cell analysis. For novel applications, researchers should perform thorough validation studies to ensure antibody specificity and sensitivity in their specific experimental system.

How can researchers effectively validate ATP5IF1 antibody specificity for their experiments?

Robust validation of ATP5IF1 antibody specificity is essential for generating reliable research findings. A comprehensive validation approach should incorporate multiple complementary strategies: (1) Western blot analysis using positive control lysates from tissues with known ATP5IF1 expression alongside negative controls; (2) Genetic approaches including siRNA/shRNA knockdown or CRISPR-Cas9 knockout models to confirm signal reduction correlates with ATP5IF1 depletion; (3) Peptide competition assays where pre-incubation with immunizing peptide should abolish specific signals; (4) Multiple antibody verification using distinct antibodies targeting different epitopes of ATP5IF1; and (5) Cross-species validation when working with non-human models. Researchers should also carefully document antibody lot numbers, dilutions, and incubation conditions to ensure experimental reproducibility.

What considerations are important when designing co-localization studies with ATP5IF1?

When designing co-localization studies involving ATP5IF1, researchers must account for its primary mitochondrial localization while recognizing potential non-canonical localizations. Studies have demonstrated that while ATP5IF1 predominantly localizes to mitochondria, it may also be present on cell surfaces in certain cell types . For successful co-localization experiments, consider the following technical aspects: (1) Select complementary fluorophores with minimal spectral overlap to avoid bleed-through artifacts; (2) Include appropriate controls for antibody cross-reactivity; (3) Employ high-resolution imaging techniques such as confocal or super-resolution microscopy to accurately resolve subcellular structures; (4) Consider the use of organelle-specific markers (e.g., MitoTracker for mitochondria) for definitive subcellular localization; and (5) Apply quantitative co-localization analysis methods rather than relying solely on visual assessment.

How can ATP5IF1 antibodies be utilized to investigate mitochondrial dysfunction in disease models?

ATP5IF1 antibodies offer valuable tools for investigating mitochondrial dysfunction across various disease models. The protein's role as an inhibitor of ATP synthase makes it a sensitive indicator of mitochondrial stress responses and metabolic adaptation. In advanced research contexts, ATP5IF1 antibodies can be employed to: (1) Quantify expression level changes in response to pathological conditions using quantitative Western blotting or ELISA approaches; (2) Assess subcellular redistribution patterns through high-resolution imaging techniques; (3) Analyze post-translational modifications via specialized immunoprecipitation protocols followed by mass spectrometry; (4) Evaluate protein-protein interaction networks through proximity ligation assays or co-immunoprecipitation experiments; and (5) Investigate dynamic regulation through live-cell imaging approaches when combined with appropriate tags. When designing such studies, researchers should consider multiple tissue types as ATP5IF1 is widely expressed across diverse tissues .

What evidence exists for non-canonical localization of ATP5IF1 and how can antibodies help investigate this phenomenon?

While ATP5IF1 is primarily recognized as a mitochondrial protein, emerging evidence suggests potential non-canonical localizations that warrant further investigation. Notably, studies similar to those conducted with ATP5B have demonstrated unexpected cell surface expression of certain ATP synthase components . To investigate such non-canonical localizations, researchers can employ selective cell surface biotinylation approaches followed by streptavidin pulldown and immunoblotting with ATP5IF1 antibodies, similar to the methodology described for ATP5B . Advanced immunofluorescence techniques, including total internal reflection fluorescence (TIRF) microscopy, can help visualize potential surface localization. Additionally, subcellular fractionation experiments followed by Western blotting analysis can provide biochemical evidence for compartment-specific distribution. These approaches require careful attention to potential cross-contamination between cellular fractions and validation with compartment-specific markers.

How can knockout/knockdown validation strategies enhance ATP5IF1 antibody studies?

Incorporating genetic manipulation approaches significantly strengthens ATP5IF1 antibody validation and experimental interpretations. For comprehensive validation studies, researchers should consider implementing: (1) siRNA or shRNA-mediated transient knockdown systems to verify antibody signal reduction correlates with ATP5IF1 depletion levels, as demonstrated in studies of related proteins like ATP5B ; (2) CRISPR-Cas9 knockout models for complete protein elimination, which provides the most stringent specificity control; (3) Rescue experiments where reintroduction of ATP5IF1 restores antibody signals in knockout backgrounds; (4) Isogenic cell line panels with varying ATP5IF1 expression levels to establish signal correlation with protein abundance; and (5) Tissue-specific conditional knockout animal models for in vivo validation studies. When utilizing these approaches, careful consideration should be given to potential compensatory mechanisms that may emerge following ATP5IF1 manipulation, particularly given its essential role in cellular energy metabolism.

What are the optimal conditions for Western blot detection of ATP5IF1?

For optimal Western blot detection of ATP5IF1, researchers should implement the following methodological considerations based on its biochemical properties as a 12.2 kDa mitochondrial protein: (1) Sample preparation should include efficient lysis buffers containing protease inhibitors to prevent degradation; (2) Higher percentage (12-15%) polyacrylamide gels are recommended for optimal resolution of this low molecular weight protein; (3) Complete transfer to PVDF membranes is typically achieved using higher current settings for shorter durations; (4) Blocking with 5% non-fat dry milk in TBS-T for 1 hour at room temperature generally provides optimal signal-to-noise ratios; (5) Primary ATP5IF1 antibody dilutions typically range from 1:500 to 1:2000 depending on the specific antibody, with overnight incubation at 4°C yielding best results; (6) Multiple washing steps (4-5 times for 5 minutes each) are crucial to minimize background; and (7) Validation with positive control lysates from tissues with known ATP5IF1 expression is essential for confirming specific detection.

How can researchers optimize immunofluorescence protocols for ATP5IF1 detection?

Successful immunofluorescence detection of ATP5IF1 requires careful optimization of multiple experimental parameters. The protocol should be customized considering: (1) Fixation method—4% paraformaldehyde for 15-20 minutes at room temperature preserves epitope accessibility while maintaining structural integrity; (2) Permeabilization—0.1-0.2% Triton X-100 for 5-10 minutes enables antibody access to mitochondrial compartments; (3) Blocking—3-5% BSA or normal serum in PBS for 30-60 minutes minimizes non-specific binding; (4) Primary antibody dilution—typically 1:100 to 1:500 depending on specific antibody characteristics, applied overnight at 4°C; (5) Secondary antibody selection—fluorophore compatibility with imaging equipment and experimental design; (6) Nuclear counterstaining—DAPI (1 μg/mL for 5 minutes) provides contextual cellular information; and (7) Mounting medium—anti-fade formulations preserve signal intensity during imaging. For mitochondrial co-localization studies, consider simultaneous staining with established markers such as MitoTracker or antibodies against other mitochondrial proteins.

What are the main technical challenges in immunoprecipitation of ATP5IF1 and how can they be addressed?

Immunoprecipitation (IP) of ATP5IF1 presents several technical challenges due to its properties as a small mitochondrial protein that forms part of a larger complex. Key challenges and corresponding solutions include: (1) Antibody specificity—validate antibodies through Western blot prior to IP applications and consider using multiple antibodies targeting different epitopes; (2) Efficient extraction—use specialized mitochondrial isolation procedures before solubilization to enrich for ATP5IF1; (3) Protein complex preservation—mild detergents like digitonin (0.5-1%) or DDM (0.5%) better preserve native protein interactions compared to more stringent detergents; (4) Cross-linking considerations—reversible cross-linkers can stabilize transient interactions before extraction; (5) Background reduction—pre-clear lysates with protein A/G beads and include appropriate negative controls using non-specific IgG; (6) Elution conditions—competitive elution with immunizing peptide may yield more specific results than conventional SDS elution; and (7) Detection sensitivity—silver staining or highly sensitive Western blotting may be required due to the small size and potentially low abundance of ATP5IF1 in certain contexts.

How has ATP5IF1 been implicated in viral infection studies and what role can antibodies play?

While ATP5IF1 itself has limited documentation in viral studies, research on related ATP synthase components provides instructive parallels. For instance, ATP5B, another subunit of the ATP synthase complex, has been identified as an interaction partner in hepatitis B virus (HBV) entry . This suggests potential roles for ATP synthase components, including possibly ATP5IF1, in viral life cycles. Antibodies against ATP5IF1 can facilitate investigation of potential virus-host interactions through: (1) Co-immunoprecipitation studies to identify viral proteins that might interact with ATP5IF1; (2) Proximity ligation assays to visualize potential interactions in situ; (3) Immunofluorescence co-localization studies to examine spatial relationships between viral components and ATP5IF1; (4) Western blot analysis to determine whether ATP5IF1 expression levels change during viral infection; and (5) Functional studies coupling antibody-based detection with viral entry or replication assays following ATP5IF1 manipulation.

How can ATP5IF1 antibodies contribute to neurodegenerative disease research?

Mitochondrial dysfunction represents a central pathological feature in numerous neurodegenerative disorders, making ATP5IF1 a potentially relevant research target in this field. ATP5IF1 antibodies can support neurodegenerative disease research through: (1) Comparative expression analysis between affected and unaffected brain regions in patient samples; (2) Co-localization studies with disease-specific protein aggregates (e.g., amyloid plaques, tau tangles) to investigate potential associations; (3) Assessment of post-translational modifications that might be altered in disease states; (4) Examination of ATP5IF1 levels in cellular and animal models following exposure to neurodegenerative stressors; and (5) Correlation of ATP5IF1 expression or localization patterns with markers of neuronal health and function. When designing such studies, researchers should consider brain region-specific expression patterns and carefully validate antibodies in neural tissues, which may present unique challenges due to high lipid content and potential cross-reactivity with neuronal proteins.

How do different antibody-based methods compare for ATP5IF1 detection sensitivity and specificity?

The selection of appropriate antibody-based detection methods for ATP5IF1 should be guided by specific research objectives and consideration of each technique's inherent strengths and limitations. The table below provides a comparative analysis of common detection methods:

Each method should be validated with appropriate positive and negative controls to ensure reliable results specific to ATP5IF1 detection.

What are the critical parameters for selecting the most appropriate anti-ATP5IF1 antibody for specific applications?

Selecting the optimal anti-ATP5IF1 antibody requires careful consideration of multiple parameters to ensure experimental success. Key selection criteria include:

• Epitope location: Antibodies targeting different regions of ATP5IF1 may yield varying results depending on protein conformation, complex formation, or post-translational modifications.

• Antibody type: Monoclonal antibodies offer high specificity for a single epitope but may be sensitive to conformational changes, while polyclonal antibodies recognize multiple epitopes providing robust detection but potentially increased background.

• Species reactivity: Confirm validated cross-reactivity with your experimental model organism, noting that ATP5IF1 orthologs exist in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken .

• Application validation: Select antibodies specifically validated for your intended application (WB, IF, IHC, etc.) with published literature support when available.

• Clonality and source: Consider the consistency requirements of your experimental design—monoclonals offer batch-to-batch consistency while polyclonals may provide greater epitope coverage.

• Detection system compatibility: Ensure compatibility with your detection method, particularly for conjugated antibodies or specialized applications.

• Validation evidence: Evaluate the quality and comprehensiveness of validation data provided by manufacturers or in published literature.

How might single-cell analysis techniques advance our understanding of ATP5IF1 function?

Emerging single-cell analysis technologies offer unprecedented opportunities to investigate ATP5IF1 function with enhanced resolution. These approaches can reveal cell-to-cell variability in ATP5IF1 expression, localization, and regulation that may be masked in bulk population studies. Promising approaches include: (1) Single-cell RNA-seq to characterize transcriptional heterogeneity of ATP5IF1 across cell populations; (2) Mass cytometry (CyTOF) incorporating ATP5IF1 antibodies to simultaneously analyze ATP5IF1 expression alongside dozens of other proteins at single-cell resolution; (3) Imaging mass cytometry for spatial analysis of ATP5IF1 distribution within tissue architecture; (4) Single-cell proteomics to quantify ATP5IF1 protein abundance variations; and (5) Live-cell imaging techniques to track real-time dynamics of ATP5IF1 in response to metabolic perturbations. These methods can particularly advance our understanding of how ATP5IF1 expression and function may vary across different cell types within heterogeneous tissues, potentially revealing context-specific roles beyond its canonical function in ATP synthesis regulation.

What novel technical approaches might improve detection of ATP5IF1's potential non-canonical locations?

Investigation of potential non-canonical localizations of ATP5IF1 beyond its well-established mitochondrial presence requires innovative technical approaches. Promising methodologies include: (1) Proximity labeling techniques such as BioID or APEX2 fused to ATP5IF1 to identify neighboring proteins in different cellular compartments; (2) Super-resolution microscopy approaches (STORM, PALM, STED) to visualize ATP5IF1 distribution with nanometer precision beyond the diffraction limit of conventional microscopy; (3) Correlative light and electron microscopy (CLEM) combining the specificity of fluorescence labeling with ultrastructural context; (4) Advanced cell surface biotinylation methods similar to those used for ATP5B with improved specificity for membrane proteins; (5) Split-fluorescent protein complementation assays to visualize ATP5IF1 interactions with proteins from different subcellular compartments; and (6) Spatial transcriptomics approaches to map ATP5IF1 mRNA localization patterns. These methods, when coupled with appropriate controls and validation strategies, can provide more definitive evidence for potential non-canonical roles and localizations of ATP5IF1.

How can systems biology approaches integrate ATP5IF1 antibody data into broader biological contexts?

Systems biology frameworks offer powerful approaches for integrating ATP5IF1 antibody-derived data into comprehensive biological models. Researchers can leverage these integrative strategies through: (1) Multi-omics data integration combining ATP5IF1 antibody-based proteomics with transcriptomics, metabolomics, and functional genomics datasets; (2) Protein interaction network analysis using ATP5IF1 immunoprecipitation data as input for interaction mapping and pathway enrichment; (3) Mathematical modeling of mitochondrial function incorporating quantitative ATP5IF1 expression data to predict metabolic responses; (4) Cross-species comparative analyses leveraging the evolutionary conservation of ATP5IF1 to identify core functional networks; and (5) Machine learning approaches to identify patterns correlating ATP5IF1 expression or localization with cellular phenotypes across large datasets. When implementing these approaches, researchers should recognize the technical limitations of antibody-based data (potential cross-reactivity, semi-quantitative nature) and incorporate appropriate normalization and validation strategies in their analytical pipelines.